Latest news with #Rule10b-5
Business Wire
5 hours ago
- Business
- Business Wire
FTRE Investors Have Opportunity to Lead Fortrea Holdings Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fortrea Holdings Inc. ('Fortrea' or 'the Company') (NASDAQ: FTRE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 3, 2023 and February 28, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 1, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Fortrea overestimated the potential revenue contributions of projects initiated prior to its spinoff from Labcorp Holdings Inc. The Company overstated the cost savings it could potentially enjoy by exiting transition services agreements ('TSAs'). The Company's EBITDA targets were inflated due to these factors. The viability of the Company's business model as well as its financial prospected were overstated. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fortrea, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
6 hours ago
- Business
- Business Wire
ECG Investors Have Opportunity to Lead Everus Construction Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Everus Construction Group, Inc. ('Everus' or 'the Company') (NYSE: ECG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and February 11, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before June 3, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Everus's backlog conversation cycle was lengthened by complex projects. The Company's revenue recognition would be delayed due to the length and complexity of its projects. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Everus, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
a day ago
- Business
- Business Wire
TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Treace Medical Concepts, Inc. ('Treace' or 'the Company') (NASDAQ: TMCI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2023 and May 7, 2024, inclusive (the 'Class Period'), are encouraged to contact the firm before June 10, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Treace suffered from competition impacting its Lapiplasty 3D Bunion Correction System (the 'Lapiplasty'). The Company's revenue declined and it felt the need to accelerate plans to offer an osteotomy alternative. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Treace, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Malaysian Reserve
a day ago
- Business
- Malaysian Reserve
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, June 2, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ('UroGen' or 'the Company') (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and May 15, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before July 28, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. UroGen's ENVISION clinical study for UGN-102 failed to demonstrate evidence of effectiveness due to its design lacking a concurrent control arm. The Company struggled to demonstrate that its duration of response endpoint could be attributed to UGN-102. The Company ignored warnings from the FDA related to its study design. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about UroGen, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law FirmBrian Schall, Esq., 310-301-3335info@
Business Wire
4 days ago
- Business
- Business Wire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ('UroGen' or 'the Company') (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and May 15, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before July 28, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. UroGen's ENVISION clinical study for UGN-102 failed to demonstrate evidence of effectiveness due to its design lacking a concurrent control arm. The Company struggled to demonstrate that its duration of response endpoint could be attributed to UGN-102. The Company ignored warnings from the FDA related to its study design. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about UroGen, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
